Incyte (INCY) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 May, 2026Executive compensation and say-on-pay
CEO William J. Meury received a one-time sign-on performance share award with a target of 125,000 shares, potentially up to 500,000 shares based on stock price performance over six years.
Shares vest in four tranches, each requiring significant sustained stock price appreciation, with hurdles set 25% to 41% higher than the previous, and the final hurdle over 2.5 times the grant date price.
As of May 27, 2026, only the first stock price hurdle had been achieved.
Performance shares are subject to service vesting, with settlement occurring between the third and sixth anniversaries of the CEO's hiring date.
The board recommends voting FOR the advisory vote to approve executive compensation, emphasizing the award's alignment with extraordinary performance.
Voting matters and shareholder proposals
Shareholders are asked to vote on Proposal 2, the Advisory Vote to Approve Executive Compensation, with the board recommending approval.
Board of directors and corporate governance
The board considers the CEO's compensation structure critical for retention and the execution of the company's next phase of growth.
Latest events from Incyte
- Diversifying portfolio and advancing late-stage assets to drive multi-billion dollar growth.INCY
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Acquisition brings a first-in-class VWD therapy with $1B+ sales potential and FDA Breakthrough status.INCY
M&A announcement8 Jun 2026 - Phase III for CALR antibody 989 in ET launches mid-year, with major pipeline and market advances.INCY
RBC Capital Markets Global Healthcare Conference 202619 May 2026 - Strong commercial growth and pipeline advances set the stage for sustained post-2029 momentum.INCY
Bank of America Global Healthcare Conference 202614 May 2026 - Multiple pivotal trials and product launches set to drive growth beyond Jakafi through 2030.INCY
Barclays 28th Annual Global Healthcare Conference11 May 2026 - Q1 2026 net sales rose 20% to $1.10B, with strong product and pipeline performance.INCY
Q1 202629 Apr 2026 - 2025 saw robust growth, pipeline advancement, and strong governance ahead of key shareholder votes.INCY
Proxy filing29 Apr 2026 - Director elections, executive pay, and auditor ratification headline the June 2026 meeting.INCY
Proxy filing29 Apr 2026 - 2025 revenue up 21% to $5.14B, core business ex-Jakafi up 53%, with strong 2026 outlook.INCY
Q4 202511 Apr 2026